

Data Sharing Statement

Tap. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. *JAMA*. Published April 07, 2020. 10.1001/jama.2020.1707

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: For details on submitting a request, see the instructions provided at www.vivli.org.

When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: Data will be made available to anyone requesting the data.

Types of analyses: Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data.

Mechanisms of data availability: Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement.

Any additional restrictions: Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment.